Novartis Pharma (encorafenib (LGX818)) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Novartis Pharma (encorafenib (LGX818)) General Information

Description

A key protein kinase in the RAS/RAF/MEK/ERK signaling pathway. It regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Primary Office
  • Boulder, CO
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis Pharma (encorafenib (LGX818)) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.

Request a free trial

Novartis Pharma (encorafenib (LGX818)) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis Pharma (encorafenib (LGX818))‘s full profile, request access.

Request a free trial